Methods for treating vascular disease
Compositions and methods included herein describe the treatment of atherosclerosis and other vascular diseases such as thrombosis, restenosis after angioplasty and/or stenting, and vein-graft disease after bypass surgery, by inhibition of the expression or biologic activity of the toll-like receptor 4 (TLR4) and/or myeloid differentiation factor 88 (MyD88). TLR4 cell signal transduction is at least partially responsible for the manifestation, continuation, and/or worsening of atherosclerosis and other forms of vascular disease. The present invention provides several means with which to inhibit this signal transduction pathway by affecting the biological activity of the TLR4 receptor and/or MyD88.
1. A method of treating a vascular disease in a subject, comprising:
(a) providing a composition comprising at least one toll-like receptor 4 (TLR4) inhibitor selected from the group consisting of hydrocinnamoyl-L-valyl pyrrolidine, anti-TLR4 antibodies ab8376 and MTS510, and combinations thereof, and at least one myeloid differentiation factor 88 (MyD88) inhibitor selected from hydrocinnamoyl-L-valyl pyrrolidine; and
(b) administering said composition to said subject in an amount effective to treat the vascular disease.
2. The method of claim 1 , wherein the vascular disease is selected from the group consisting of atherosclerosis, transplant atherosclerosis, vein-graft atherosclerosis, thrombosis, restenosis, stent restenosis, and angioplasty restenosis.
3. The method of claim 1 , wherein said subject is a human.
4. The method of claim 1 , wherein the route of administration is oral, parenteral or via implantation.
5. The method of claim 1 , wherein administering the composition further comprises delivering the composition with an intravascular device.
6. The method of claim 5 , wherein the intravascular device is a catheter or a stent.
7. The method of claim 6 , wherein the intravascular device is coated with the composition.
8. The method of claim 1 , where the disease is atherosclerosis.
9. The method of claim 1 , wherein said composition includes a pharmaceutically acceptable carrier.
10. The method of claim 1 , wherein the TLR4 inhibitor is hydrocinnamoyl-L-valyl pyrrolidine.
11. The method of claim 1 , wherein the TLR4 inhibitor is anti-TLR4 antibody ab8376.
12. The method of claim 1 , wherein the TLR4 inhibitor is anti-TLR4 antibody MTS510.
13. The method of claim 1 , wherein the MyD88 inhibitor is hydrocinnamoyl-L-valyl pyrrolidine.